<DOC>
	<DOC>NCT00414206</DOC>
	<brief_summary>This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration (NV-AMD).</brief_summary>
	<brief_title>Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Mecamylamine</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>AMD</keyword>
	<keyword>Wet AMD</keyword>
</DOC>